181.80
price down icon1.65%   -3.05
after-market After Hours: 181.30 -0.50 -0.28%
loading
Abbvie Inc stock is traded at $181.80, with a volume of 4.82M. It is down -1.65% in the last 24 hours and up +6.84% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$184.85
Open:
$183.93
24h Volume:
4.82M
Relative Volume:
0.63
Market Cap:
$321.13B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
77.36
EPS:
2.35
Net Cash Flow:
$15.39B
1W Performance:
+2.46%
1M Performance:
+6.84%
6M Performance:
+5.86%
1Y Performance:
+11.58%
1-Day Range:
Value
$181.54
$184.81
1-Week Range:
Value
$176.57
$186.00
52-Week Range:
Value
$153.58
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
55,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
181.80 313.43B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
724.95 642.38B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.18 352.15B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
112.78 207.36B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.20 286.20B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
May 21, 2025

AbbVie Gets Victory In Allergan Shareholder Suit Upheld - Law360

May 21, 2025
pulisher
May 21, 2025

Court upholds dismissal of AbbVie-Allergan merger suit - Crain's Chicago Business

May 21, 2025
pulisher
May 21, 2025

AbbVie, Allergan Merger Suit Dismissal Upheld By Illinois Court - Bloomberg Law News

May 21, 2025
pulisher
May 21, 2025

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView

May 21, 2025
pulisher
May 21, 2025

Cancer Cachexia Market Detailed in New Research Report By 2032 | AbbVie Inc., Actimed Therapeutics - openPR.com

May 21, 2025
pulisher
May 21, 2025

Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Plastic Surgery Market Fly Massive Growth in Years to Come: AbbVie, Johnson & Johnson Services, Sientra - openPR.com

May 21, 2025
pulisher
May 20, 2025

AbbVie Hits Last Generic-Orilissa Holdout With New Patent Suit - Bloomberg Law News

May 20, 2025
pulisher
May 20, 2025

Ameriprise Financial Initiates AbbVie at Buy - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

AbbVie (ABBV) Soared on Favorable Tailwinds - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class ActionABBV - Morningstar

May 20, 2025
pulisher
May 20, 2025

Former AbbVie, Takeda omnichannel lead Dan Gandor joins Eversana Intouch - Medical Marketing and Media

May 20, 2025
pulisher
May 19, 2025

Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.

May 19, 2025
pulisher
May 19, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class ActionABBV - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie - TradingView

May 19, 2025
pulisher
May 17, 2025

Perion, Sea, KKR, Chimera, AbbVie: Trending by Analysts - TipRanks

May 17, 2025
pulisher
May 16, 2025

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock” - MSN

May 16, 2025
pulisher
May 16, 2025

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - simplywall.st

May 16, 2025
pulisher
May 16, 2025

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

3 Stocks That Will Profit From Trump's Drug Price CutAbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN) - Benzinga

May 16, 2025
pulisher
May 16, 2025

Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - TradingView

May 16, 2025
pulisher
May 15, 2025

7th Circ. Weighs AbbVie Whistleblower's Drug Marketing Suit - Law360

May 15, 2025
pulisher
May 15, 2025

AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer - MedCity News

May 15, 2025
pulisher
May 15, 2025

FDA awards cancer drug approvals to AbbVie and MSD - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV - TradingView

May 15, 2025
pulisher
May 15, 2025

AbbVie stakes $335M on a startup’s RNAi drugs - BioPharma Dive

May 15, 2025
pulisher
May 15, 2025

FDA Approves AbbVie’s Emrelis - The Pharma Letter

May 15, 2025
pulisher
May 15, 2025

Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 - Benzinga

May 15, 2025
pulisher
May 15, 2025

AbbVie & ADARx Partner on Next-Gen siRNA Therapeutics - Contract Pharma

May 15, 2025
pulisher
May 15, 2025

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Psoriasis Drugs Market Set to Witness Significant Growth by 2033 - openPR.com

May 15, 2025
pulisher
May 15, 2025

AbbVie and ADARx Pharmaceuticals Announce Collaboration - citybiz

May 15, 2025
pulisher
May 15, 2025

AbbVie bags first approval for cancer ADC Emrelis - Pharmaphorum

May 15, 2025
pulisher
May 15, 2025

AbbVie expands siRNA push with $335m ADARx deal - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

AbbVie Emrelis gets USFDA accelerated approval for a type of lung cancer - Medical Dialogues

May 15, 2025
pulisher
May 14, 2025

Regeneron Upgraded as AbbVie Catches Policy Heat - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Buy Rating for AbbVie’s Emrelis Supported by FDA Approval and Promising NSCLC Treatment Potential - TipRanks

May 14, 2025
pulisher
May 14, 2025

US FDA approves AbbVie's drug for a type of lung cancer - Reuters

May 14, 2025
pulisher
May 14, 2025

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics - insights.citeline.com

May 14, 2025
pulisher
May 14, 2025

Yes siRNA: Adarx/Abbvie tie-up worth “several billion” dollars - BioWorld MedTech

May 14, 2025
pulisher
May 14, 2025

AbbVie On MFN: ‘We Have To Take It Seriously’ - insights.citeline.com

May 14, 2025
pulisher
May 14, 2025

Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer (NYSE:ABBV) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

US FDA approves AbbVie’s drug for a type of lung cancer - 1470 & 100.3 WMBD

May 14, 2025
pulisher
May 14, 2025

AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies - Dermatology Times

May 14, 2025
pulisher
May 14, 2025

US FDA clears Abbvie’s c-Met lung cancer ADC - BioWorld MedTech

May 14, 2025
pulisher
May 14, 2025

FDA Grants Accelerated Approval to AbbVie's Emrelis for Lung Can - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Transcript : AbbVie Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

AbbVie (ABBV) Gains FDA Accelerated Approval for Emrelis | ABBV Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

AbbVie wins approval of Emrelis for non-small cell lung cancer - Seeking Alpha

May 14, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$153.18
price down icon 0.31%
drug_manufacturers_general NVS
$112.78
price up icon 0.45%
drug_manufacturers_general NVO
$68.20
price up icon 0.00%
drug_manufacturers_general MRK
$76.98
price down icon 1.27%
drug_manufacturers_general GSK
$38.54
price up icon 0.36%
Cap:     |  Volume (24h):